All 50 States Apply to Join Medicaid’s GENEROUS Drug Pricing Model

On September 18, 2026, the White House and the Centers for Medicare & Medicaid Services (CMS) announced that Medicaid programs in all 50 states, the District of Columbia and Puerto Rico have applied to join GENEROUS, a federal payment model meant to bring Medicaid’s net prescription drug prices in line with what certain other countries pay. According to CMS, 40 states and Puerto Rico have already signed participation agreements. The remaining states have until September 30, 2026 to finalize their applications.

What GENEROUS is

GENEROUS stands for GENErating cost Reductions fOr U.S. Medicaid. It is a model run by the CMS Innovation Center. CMS says it launched in January 2026 and runs for five years. Participation is voluntary for both drug manufacturers and states.

The mechanism, as CMS describes it, works through supplemental rebates. Manufacturers report their international net unit prices to CMS. States then invoice manufacturers quarterly for a rebate that reflects the difference between the current U.S. price and what certain other countries pay. The model covers single-source and innovator multiple-source covered outpatient drugs from participating manufacturers, and states can choose which of those drugs to include.

The White House fact sheet says the administration has agreements with 26 manufacturers covering 89% of the branded drug market. It names Pfizer, Eli Lilly, Novo Nordisk, Merck and Johnson & Johnson among them, and says the agreements cover hundreds of drugs across major classes, including oncology, diabetes care and asthma.

What the numbers say

• $64.3 billion: estimated savings in Medicaid drug costs over ten years, according to the Council of Economic Advisers.
• $36.6 billion of that would accrue to the federal government and $27.6 billion to state governments, per the White House fact sheet.
• $60 billion: Medicaid drug spending in 2024, up $10 billion from 2022, according to CMS.

What the announcement does not show

These are projections, not measured results. The CMS press release does not say how the $64.3 billion estimate was calculated, and it does not break the savings down by state or by drug. It also does not list which specific drugs are covered, so a reader cannot tell from the announcement how much of any one state’s spending is affected.

The international prices that drive the rebates are reported by manufacturers to CMS. The public materials we reviewed do not say whether those prices, or the rebate amounts, will be published. The two official descriptions are also worded differently. The White House says final Medicaid prices will not exceed the most-favored-nation price, while CMS describes supplemental rebates that “reflect the international pricing.” How the two fit together in practice is not spelled out in the pages we read.

One technical detail matters for other federal programs. CMS states that the supplemental rebates under GENEROUS do not change Medicaid Best Price, and therefore do not affect 340B Drug Discount Program ceiling prices.

How the savings reach the states

States do not simply keep the rebates. CMS says it shares them with states through a reduction in the federal share of Medicaid payments. Participating states must also meet management, operational and system requirements, including aligning coverage policies with their Medicaid managed care organizations. What those requirements cost states to implement is not stated.

What remains unknown

• Which individual drugs each state will include, and when prices change at the pharmacy counter.
• Whether patients will see any difference in coverage or out-of-pocket costs. The announcements describe savings to governments, not to enrollees.
• How the savings estimate was built, and what happens to it if fewer manufacturers or drugs participate than assumed.
• What happens to the model after its five-year term.

Why it matters

Medicaid is one of the largest single purchasers of prescription drugs in the country, and the model is the administration’s attempt to use that purchasing position to align U.S. net prices with international benchmarks. The near-universal state sign-up shows that states see the rebates as worth the operational work. Whether the projected savings materialize will depend on details the public announcements have not yet provided: the drug list, the international price data and the quarterly invoicing results.

This article is general information, not medical or legal advice.

Sources: CMS, GENEROUS Model page; CMS press release of September 18, 2026; White House fact sheet of September 18, 2026.